Hologic Adds Gynesonics' Sonata System In $350M Acquisition To Boost Fibroid Treatments

On Monday, Hologic Inc (NASDAQ:HOLX) agreed to acquire  Gynesonics, Inc. for approximately $350 million.

Gynesonics is a privately held medical device company that develops minimally invasive solutions for women’s health.

California-based Gynesonics develops and sells the Sonata System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding.

The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.

Also Read: Women’s Health-Focused Hologic Has Significant Capacity For Expansion Via M&A, Bullish Analyst Says.

William Blair writes that Sonata System’s approach differs from Hologic’s Acessa device/ procedure, which delivers imaging and radiofrequency heat through two small abdominal incisions.

Hologic’s MyoSure device/procedure is also a solution ...